Cardium's Corgentin (Ad5IGF-I) preclinical product candidate is a next-generation DNA-based therapeutic using the insulin-like growth factor-I gene carried by an adenovector that is being developed as a potential one-time treatment to promote the preservation and restoration of heart tissue and cardiac function following a heart attack (acute myocardial infarction). Cardium believes that Corgentin, which effectively enables prolonged IGF-I expression within the heart muscle, offers the potential to prevent further damage to heart muscle and improve cardiac healing following a heart attack. The inherent biological properties of IGF-I, which include inhibition of cardiomyocyte apoptosis, adaptive cardiomyocyte hypertrophy, recruitment of cardiac progenitor cells, as well as the induction of angiogenesis and enhancement of cardiac function, combined with Cardium's delivery approach to yield sustained localized expression, provide the rationale for the development of a therapy directed at myocardial repair and restoration. This combination of positive biological attributes and effective delivery supports the potential of Corgentin to improve functional recovery and prevent ventricular dysfunction and the associated progression to congestive heart failure following myocardial infarction and reperfusion.
According to the American Heart Association, the estimated annual incidence of myocardial infarction (MI) is 600,000 new attacks and 320,000 recurrent attacks. Even with the best of care and successful early intervention, such as tissue plasminogen activator (tPA) or emergency angioplasty, about 30% of heart attack patients will eventually go on to develop decompensation through ventricular remodeling and progressive congestive heart failure. This explains in large part why heart failure remains an epidemic health problem despite improved treatments for acute cardiac events.
The safety of systemic IGF-I pr
|SOURCE Cardium Therapeutics, Inc.|
Copyright©2008 PR Newswire.
All rights reserved